医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Ball Wave, a Startup from Tohoku University

2020年11月30日 PM01:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested1 in Ball Wave Inc., a startup from Tohoku University that develops practical applications of ball SAW sensors.2 These sensors use natural collimation of surface acoustic waves (SAWs), a physical phenomenon predicted and experimentally verified by researchers at Tohoku University, and can instantly detect various kinds of matter in air and other gases at the nanoscale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201129005111/en/

Ball SAW sensor (Graphic: Business Wire)

Ball SAW sensor (Graphic: Business Wire)

Toyoda Gosei and Ball Wave will leverage Toyoda Gosei’s surface treatment technologies, such as painting and plating technology cultivated in the development and production of automotive interiors and exteriors, to achieve coatings for better ball SAW sensor performance. In the future, the two companies aim to develop a sensor that can detect viruses in the air with a view to combining it with Toyoda Gosei’s deep UV LED technology that can eliminate the novel coronavirus and other viruses.

Toyoda Gosei will continue to tackle social issues through collaboration with startups that are promising for synergy with its core technologies.

*1

100 million yen was invested in November 2020.

*2

Ball Wave has commercialized devices such as a high-performance trace moisture sensor that can be used in semiconductor manufacturing processes and drying rooms.

Company outline of Ball Wave

Company name

Ball Wave Inc.

Headquarters

Tohoku University Business Incubator T-Biz 501, 6-6-40, Aza Aoba, Aramaki, Aoba, Sendai, Miyagi

President & CEO

Dr. Shingo Akao

Founded

November, 2015

Capital

JPY100 million (as of October, 2020)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201129005111/en/

CONTACT

Toyoda Gosei Co., Ltd.

Takatomo Abe

inquiry@mail.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network
  • Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies